vs
Anteris Technologies Global Corp.（AVR）与Enovis CORP（ENOV）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是Anteris Technologies Global Corp.的1770.7倍（$548.9M vs $310.0K）。Enovis CORP净利率更高（-104.1% vs -9420.0%，领先9315.9%）。Enovis CORP自由现金流更多（$29.1M vs $-18.9M）
Anteris Technologies Global Corp是一家专注于结构性心脏病诊疗解决方案的医疗科技企业，开发及商业化生物假体心脏瓣膜、经导管介入产品，服务北美、欧洲及亚太地区的医疗机构，核心业务覆盖心脏外科与介入心脏病学领域。
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
AVR vs ENOV — 直观对比
营收规模更大
ENOV
是对方的1770.7倍
$310.0K
净利率更高
ENOV
高出9315.9%
-9420.0%
自由现金流更多
ENOV
多$48.0M
$-18.9M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $310.0K | $548.9M |
| 净利润 | $-29.2M | $-571.1M |
| 毛利率 | 70.6% | 59.9% |
| 营业利润率 | -9343.5% | -101.7% |
| 净利率 | -9420.0% | -104.1% |
| 营收同比 | — | -2.2% |
| 净利润同比 | — | 18.8% |
| 每股收益（稀释后） | $-0.74 | $-9.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVRENOV
| Q4 25 | $310.0K | $548.9M | ||
| Q3 25 | $429.0K | $564.5M | ||
| Q2 25 | $618.0K | $558.8M | ||
| Q1 25 | $556.0K | — | ||
| Q4 24 | — | $561.0M | ||
| Q3 24 | — | $505.2M | ||
| Q2 24 | — | $525.2M | ||
| Q1 24 | — | $516.3M |
净利润AVRENOV
| Q4 25 | $-29.2M | $-571.1M | ||
| Q3 25 | $-22.2M | $-36.7M | ||
| Q2 25 | $-20.8M | $-56.0M | ||
| Q1 25 | $-21.9M | — | ||
| Q4 24 | — | $-703.2M | ||
| Q3 24 | — | $-31.5M | ||
| Q2 24 | — | $-18.6M | ||
| Q1 24 | — | $-72.0M |
毛利率AVRENOV
| Q4 25 | 70.6% | 59.9% | ||
| Q3 25 | 71.3% | 59.3% | ||
| Q2 25 | 76.1% | 59.5% | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 56.7% | ||
| Q2 24 | — | 55.0% | ||
| Q1 24 | — | 57.7% |
营业利润率AVRENOV
| Q4 25 | -9343.5% | -101.7% | ||
| Q3 25 | -5190.0% | -3.0% | ||
| Q2 25 | -3379.3% | -8.4% | ||
| Q1 25 | -3917.3% | — | ||
| Q4 24 | — | -118.5% | ||
| Q3 24 | — | -6.3% | ||
| Q2 24 | — | -8.4% | ||
| Q1 24 | — | -6.8% |
净利率AVRENOV
| Q4 25 | -9420.0% | -104.1% | ||
| Q3 25 | -5185.1% | -6.5% | ||
| Q2 25 | -3371.2% | -10.0% | ||
| Q1 25 | -3932.4% | — | ||
| Q4 24 | — | -125.4% | ||
| Q3 24 | — | -6.2% | ||
| Q2 24 | — | -3.5% | ||
| Q1 24 | — | -13.9% |
每股收益（稀释后）AVRENOV
| Q4 25 | $-0.74 | $-9.99 | ||
| Q3 25 | $-0.62 | $-0.64 | ||
| Q2 25 | $-0.58 | $-0.98 | ||
| Q1 25 | $-0.61 | — | ||
| Q4 24 | — | $-12.69 | ||
| Q3 24 | — | $-0.58 | ||
| Q2 24 | — | $-0.34 | ||
| Q1 24 | — | $-1.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $33.6M |
| 总债务越低越好 | $22.0K | $1.4B |
| 股东权益账面价值 | $-93.0K | $2.0B |
| 总资产 | $23.0M | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资AVRENOV
| Q4 25 | — | $33.6M | ||
| Q3 25 | — | $44.1M | ||
| Q2 25 | — | $38.5M | ||
| Q1 25 | $49.0M | — | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | — | $35.4M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $66.3M |
总债务AVRENOV
| Q4 25 | $22.0K | $1.4B | ||
| Q3 25 | $26.0K | $1.4B | ||
| Q2 25 | $30.0K | $1.4B | ||
| Q1 25 | $30.0K | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
股东权益AVRENOV
| Q4 25 | $-93.0K | $2.0B | ||
| Q3 25 | $3.7M | $2.6B | ||
| Q2 25 | $24.4M | $2.6B | ||
| Q1 25 | $43.3M | — | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | $3.3B |
总资产AVRENOV
| Q4 25 | $23.0M | $4.4B | ||
| Q3 25 | $19.1M | $5.0B | ||
| Q2 25 | $39.9M | $4.9B | ||
| Q1 25 | $58.8M | — | ||
| Q4 24 | — | $4.7B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $5.5B |
负债/权益比AVRENOV
| Q4 25 | — | 0.67× | ||
| Q3 25 | 0.01× | 0.54× | ||
| Q2 25 | 0.00× | 0.53× | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.5M | $82.6M |
| 自由现金流经营现金流 - 资本支出 | $-18.9M | $29.1M |
| 自由现金流率自由现金流/营收 | -6104.5% | 5.3% |
| 资本支出强度资本支出/营收 | 128.1% | 9.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-79.8M | $22.8M |
8季度趋势，按日历期对齐
经营现金流AVRENOV
| Q4 25 | $-18.5M | $82.6M | ||
| Q3 25 | $-18.3M | $47.8M | ||
| Q2 25 | $-19.5M | $-1.6M | ||
| Q1 25 | $-21.5M | — | ||
| Q4 24 | — | $88.3M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | — | $7.8M | ||
| Q1 24 | — | $-36.2M |
自由现金流AVRENOV
| Q4 25 | $-18.9M | $29.1M | ||
| Q3 25 | $-19.0M | $3.4M | ||
| Q2 25 | $-20.1M | $-44.9M | ||
| Q1 25 | $-21.7M | — | ||
| Q4 24 | — | $35.1M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | $-31.6M | ||
| Q1 24 | — | $-73.1M |
自由现金流率AVRENOV
| Q4 25 | -6104.5% | 5.3% | ||
| Q3 25 | -4434.5% | 0.6% | ||
| Q2 25 | -3247.9% | -8.0% | ||
| Q1 25 | -3909.5% | — | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | -6.0% | ||
| Q1 24 | — | -14.2% |
资本支出强度AVRENOV
| Q4 25 | 128.1% | 9.7% | ||
| Q3 25 | 180.0% | 7.9% | ||
| Q2 25 | 86.9% | 7.7% | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | — | 7.5% | ||
| Q1 24 | — | 7.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVR
暂无分部数据
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
